1. Medtech Insight
  2. >>Device Area

Less Is More: On-Demand Robotics Can Be The Way Forward In Minimally Invasive Surgery

 
• By Ashley Yeo

Robotics means different things to different surgeons, according to Swiss innovator Distalmotion, whose surgical robot combines with laparoscopy to leave the surgeon fully in control in the OR.

source: Distalmotion

Swiss company Distalmotion is pioneering novel hybrid robotic surgery devices. The company’s Dexter device combines laparoscopy and robotics for use in soft tissue, uro/gyne and general surgery.

Uniquely, it allows the surgeon to stay scrubbed in at the patient and to remain in full control of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gynecology and Urology

FDA Publishes Updated ‘Roadmap’ For Advancing Women’s Health

 
• By Brian Bossetta

The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

 
• By Brian Bossetta, Marion Webb, Elizabeth Orr, and Natasha Barrow

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.  

News We’re Watching: Neuralink’s Blindsight Gets FDA Breakthrough Device Tag; FDA Pump Recalls, Guidances; Discure, DeepLook Bolster Coffers

 
• By Marion Webb, Brian Bossetta, Elizabeth Orr, and Natasha Barrow

This week, Neuralink announced it received US FDA breakthrough device designation for a device to restore sight; medtechs Discure and DeepLook secured new funding; FDA pump recalls from B. Braun Medical and Fresenius Kabi; Axonics prevails in patent infringement lawsuit with Medtronic; Merit Medical buys Cook Medical for $210m.

Prodded By Congress, FDA Launches Tampon Review

 
• By Elizabeth Orr

The US agency said on 10 September that it plans to study whether heavy metals detected in tampons could endanger their users.

More from Device Area

LDTs Aimed At Catching Cancers Early Hold Promise In Reducing Late-Stage Diagnoses, Study Shows

 
• By Brian Bossetta

A recent study demonstrates that certain types of blood-based tests that screen for multiple cancers at once have the potential to flip the script on cancer diagnoses, including some of the deadliest types.

Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

 
• By Barnaby Pickering

Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.

Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market

 
• By Marion Webb

Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.